|
|
|
Sunday, February 12, 2006 — 1:30 PM — Centennial I
|
- Surface Epithelial Tumors of the Ovary — Part 1: Borderline Tumors - Current State of the Art
|
|
Moderator:
|
Robert J. Kurman, Johns Hopkins University School of Medicine, Baltimore, MD
|
|
|
Disclosure:
|
The speakers have indicated they have nothing to disclose. | | |  Click here to view images of Non-Invasive vs. Invasive Implants that will be reviewed
at the Symposium and discussed by the panel. (9.2MB)
|
Click here to download handout in 1-per-page format for the entire meeting (18.9MB)
Click here to download handout in 6-per-page format for the entire meeting (18.8MB)
Click any blue title below to display and print the handout for individual lecture(s):
| 1:30 | Introduction - Robert J. Kurman, Johns Hopkins University School of Medicine, Baltimore, MD |
| 2:00 | Relationship to Invasive Carcinoma - Ie-Ming Shih, Johns Hopkins University School of Medicine, Baltimore, MD |
| 2:30 | Significance of Microinvasion and Lymph Node Involvement - Teri Longacre, Stanford University School of Medicine, Stanford, CA |
| 3:00 | Break |
| 3:30 | Significance of Invasive Versus Noninvasive Implants - Elvio Silva, M.D. Anderson Hospital, Houston, TX Click here for references. |
| 4:00 | Criteria for the Diagnosis of Implants - Debra Bell, Massachusetts General Hospital, Boston, MA Click here for references. |
| 4:30 | Panel Discussion |
| The subject of borderline ovarian tumors is undoubtedly the most poorly understood and controversial area in gynecological pathology today. Criteria for their diagnosis, in particular for the evaluation of extraovarian disease (implants) are not well defined and not consistently applied. Accordingly, pathologists in practice find this an extremely difficult area. Hence this topic was selected. Borderline ovarian tumors have not been the subject of a symposium for over ten years. The objective is to review the current understanding of the pathogenesis and behavior of borderline ovarian tumors and to review criteris for diagnosis of the primary ovarian tumor and the implants. |
|
|
|
